ATE534645T1 - Kaliumsalz eines hiv-integrasehemmers - Google Patents
Kaliumsalz eines hiv-integrasehemmersInfo
- Publication number
- ATE534645T1 ATE534645T1 AT05852840T AT05852840T ATE534645T1 AT E534645 T1 ATE534645 T1 AT E534645T1 AT 05852840 T AT05852840 T AT 05852840T AT 05852840 T AT05852840 T AT 05852840T AT E534645 T1 ATE534645 T1 AT E534645T1
- Authority
- AT
- Austria
- Prior art keywords
- potassium salt
- hiv integrase
- integrase inhibitor
- inhibitor
- hiv
- Prior art date
Links
- 229940099797 HIV integrase inhibitor Drugs 0.000 title 1
- 239000003084 hiv integrase inhibitor Substances 0.000 title 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63313204P | 2004-12-03 | 2004-12-03 | |
| PCT/US2005/043728 WO2006060712A2 (en) | 2004-12-03 | 2005-12-02 | Potassium salt of an hiv integrase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE534645T1 true ATE534645T1 (de) | 2011-12-15 |
Family
ID=36171569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05852866T ATE518844T1 (de) | 2004-12-03 | 2005-12-02 | Kaliumsalz eines hiv-integrase-inhibitors |
| AT05852840T ATE534645T1 (de) | 2004-12-03 | 2005-12-02 | Kaliumsalz eines hiv-integrasehemmers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05852866T ATE518844T1 (de) | 2004-12-03 | 2005-12-02 | Kaliumsalz eines hiv-integrase-inhibitors |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7754731B2 (de) |
| EP (2) | EP1819700B1 (de) |
| JP (1) | JP4705956B2 (de) |
| KR (2) | KR20130122031A (de) |
| CN (1) | CN101068793B (de) |
| AR (2) | AR052034A1 (de) |
| AT (2) | ATE518844T1 (de) |
| AU (1) | AU2005311671B8 (de) |
| BR (1) | BRPI0518760A8 (de) |
| CA (1) | CA2588398C (de) |
| CR (1) | CR9146A (de) |
| CY (1) | CY1112859T1 (de) |
| DK (1) | DK1819700T3 (de) |
| EA (1) | EA012418B1 (de) |
| ES (2) | ES2370136T3 (de) |
| GE (1) | GEP20105086B (de) |
| HR (1) | HRP20120066T1 (de) |
| IL (1) | IL183614A (de) |
| MA (1) | MA29120B1 (de) |
| ME (1) | ME01985B (de) |
| MX (1) | MX2007006639A (de) |
| MY (1) | MY144320A (de) |
| NI (1) | NI200700138A (de) |
| NO (1) | NO338784B1 (de) |
| NZ (1) | NZ555376A (de) |
| PE (1) | PE20061148A1 (de) |
| PL (1) | PL1819700T3 (de) |
| PT (1) | PT1819700E (de) |
| RS (1) | RS52197B (de) |
| SI (1) | SI1819700T1 (de) |
| TN (1) | TNSN07215A1 (de) |
| TW (1) | TWI344463B (de) |
| UA (1) | UA87884C2 (de) |
| WO (2) | WO2006060712A2 (de) |
| ZA (1) | ZA200704130B (de) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1725528T3 (pl) | 2004-03-11 | 2013-12-31 | 4Sc Ag | Sulfonylopirole jako inhibitory HDAC |
| US20070259894A1 (en) * | 2004-12-03 | 2007-11-08 | Kelem Kassahun | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 |
| EP2586444B1 (de) * | 2004-12-03 | 2019-09-25 | Merck Sharp & Dohme Corp. | Pharmazeutische Formulierung von Carbonsäureamid-HIV-Integraseinhibitoren mit einer Zusammensetzung zur Steuerung der Abgabenrate |
| ES2727577T5 (en) * | 2004-12-03 | 2025-04-02 | Merck Sharp & Dohme Llc | Pharmaceutical composition containing an anti-nucleating agent |
| TW200810789A (en) * | 2006-03-14 | 2008-03-01 | Merck & Co Inc | Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use |
| WO2008010953A2 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
| WO2009009531A2 (en) * | 2007-07-09 | 2009-01-15 | Concert Pharmaceuticals Inc. | Pyrimidinecarboxamide derivatives for the treatment of hiv infections |
| CN101918372B (zh) * | 2008-01-08 | 2014-03-26 | 默沙东公司 | 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法 |
| ES2549387T3 (es) * | 2009-06-02 | 2015-10-27 | Hetero Research Foundation | Procedimiento de preparación de raltegravir potásico amorfo |
| WO2011024192A2 (en) | 2009-07-27 | 2011-03-03 | Matrix Laboratories Ltd | Novel polymorphs of raltegravir |
| EP3970702A1 (de) | 2009-10-26 | 2022-03-23 | Merck Sharp & Dohme Corp. | Feste pharmazeutische zusammensetzungen mit einem integrasehemmer |
| DE102009056636A1 (de) | 2009-12-02 | 2011-06-09 | Ratiopharm Gmbh | Raltegravir-Polymorphe |
| AU2010328325B2 (en) | 2009-12-07 | 2015-02-05 | University Of Georgia Research Foundation, Inc. | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications |
| ES2362598B1 (es) * | 2009-12-17 | 2012-06-13 | Consejo Superior De Investigaciones Científicas (Csic) | Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus. |
| EP2545048B1 (de) * | 2010-04-01 | 2014-10-08 | Teva Pharmaceutical Industries Ltd. | Raltegravirsalze und kristalline formen davon |
| US8987272B2 (en) * | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
| WO2011148381A1 (en) * | 2010-05-25 | 2011-12-01 | Hetero Research Foundation | Salts of raltegravir |
| US9107922B2 (en) | 2010-07-16 | 2015-08-18 | Concert Pharmaceuticals, Inc. | Pyrimidinecarboxamide derivatives |
| CN101914067B (zh) * | 2010-08-26 | 2012-07-11 | 陈岱岭 | N-甲基嘧啶酮的合成方法 |
| JO3209B1 (ar) * | 2010-11-05 | 2018-03-08 | H Lundbeck As | طريقة لتصنيع نالتريكسون |
| WO2012103105A1 (en) | 2011-01-24 | 2012-08-02 | Assia Chemical Industries Ltd. | Processes for preparing raltegravir and intermediates in the processes |
| WO2012106534A2 (en) * | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
| US9163009B2 (en) | 2011-04-06 | 2015-10-20 | Lupin Limited | Salts of raltegravir |
| EP2699094A4 (de) * | 2011-04-22 | 2014-12-17 | Merck Sharp & Dohme | Geschmacksmaskierte formulierungen von raltegravir |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| EP2522665A1 (de) | 2011-05-03 | 2012-11-14 | Sandoz Ag | Kristallinnatriumsalz eines HIV-Integrasehemmers |
| ES2450944T3 (es) | 2011-06-01 | 2014-03-25 | Ratiopharm Gmbh | Composición y comprimido que comprenden raltegravir |
| EP2755968A1 (de) | 2011-09-16 | 2014-07-23 | Hexal AG | Neue polymorphe form von raltegravir-kalium |
| CN103130788B (zh) * | 2011-11-24 | 2015-09-02 | 南开大学 | 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| CN103130787B (zh) * | 2011-11-24 | 2015-06-10 | 南开大学 | 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| WO2013098854A2 (en) * | 2011-12-26 | 2013-07-04 | Emcure Pharmaceuticals Limited | Synthesis of raltegravir |
| MX2014009015A (es) | 2012-01-25 | 2014-12-08 | Lupin Ltd | Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma. |
| WO2014064711A2 (en) * | 2012-10-22 | 2014-05-01 | Hetero Research Foundation | Methods of administering raltegravir and raltegravir compositions |
| EP2818470A1 (de) | 2013-06-27 | 2014-12-31 | Basf Se | Kokristalle von Raltegravir-Kalium |
| WO2015009927A1 (en) * | 2013-07-17 | 2015-01-22 | Ratiopharm Gmbh | Dolutegravir salts |
| US20170253585A1 (en) | 2014-02-03 | 2017-09-07 | Mylan Laboratories Ltd. | Processes for the preparation of intermediates of raltegravir |
| EP3119773A1 (de) | 2014-03-21 | 2017-01-25 | Mylan Laboratories Ltd. | Vormischung von kristallinem raltegravir-potassium-salz und verfahren zur herstellung davon |
| US10257840B2 (en) | 2014-10-22 | 2019-04-09 | Telefonaktiebolaget Lm Ericsson (Publ) | Operation of wireless local area network in the presence of periodic interference |
| WO2016075605A1 (en) | 2014-11-10 | 2016-05-19 | Aurobindo Pharma Ltd | An improved process for the preparation of raltegravir |
| EP3472134B1 (de) * | 2016-06-21 | 2021-10-20 | Pharmathen S.A. | Verfahren zur herstellung von verbindungen als zwischenprodukte zur herstellung von raltegravir |
| AU2017329049A1 (en) | 2016-09-15 | 2019-04-04 | Lupin Limited | Process for the preparation of pure and stable crystalline Raltegravir potassium Form 3 |
| CN108610338A (zh) * | 2016-12-12 | 2018-10-02 | 天津国际生物医药联合研究院 | 一种嘧啶酮酰胺类化合物的制备方法 |
| US11246869B2 (en) | 2017-11-14 | 2022-02-15 | Cambrex Profarmaco Milano S.R.L. | Process for the preparation of Raltegravir |
| EP3801532B1 (de) * | 2018-06-06 | 2025-11-05 | Merck Sharp & Dohme LLC | Formulierungen von raltegravir |
| GB201907305D0 (en) * | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| US12465565B2 (en) | 2020-01-23 | 2025-11-11 | Lupin Limited | Pharmaceutical compositions of raltegravir |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH624391A5 (de) * | 1976-12-14 | 1981-07-31 | Ciba Geigy Ag | |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5717097A (en) | 1991-11-08 | 1998-02-10 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| IL121789A (en) * | 1996-10-03 | 2001-06-14 | Rohm & Haas | A medicinal product for inhibiting mammalian cell tumors |
| ID29027A (id) | 1998-12-25 | 2001-07-26 | Shionogi & Co | Turunan-turunan heteroaromatik yang mempunyai aktivitas penghambatan terhadap integrase hiv |
| IT1318424B1 (it) | 2000-03-24 | 2003-08-25 | Unihart Corp | Composti con attivita' anti-hiv. |
| WO2002030931A2 (en) | 2000-10-12 | 2002-04-18 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| GB0028483D0 (en) | 2000-11-22 | 2001-01-10 | Hoffmann La Roche | Hydroxyethylamine HIV protease inhibitors |
| HU230248B1 (hu) * | 2001-10-26 | 2015-11-30 | Msd Italia S.R.L. | N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok |
| BRPI0215050B8 (pt) | 2001-12-21 | 2021-05-25 | Anormed Inc | compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7176220B2 (en) | 2002-11-20 | 2007-02-13 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
| MXPA05007010A (es) | 2002-12-27 | 2005-08-18 | Angeletti P Ist Richerche Bio | Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana. |
| TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| EP2586444B1 (de) | 2004-12-03 | 2019-09-25 | Merck Sharp & Dohme Corp. | Pharmazeutische Formulierung von Carbonsäureamid-HIV-Integraseinhibitoren mit einer Zusammensetzung zur Steuerung der Abgabenrate |
| ES2727577T5 (en) | 2004-12-03 | 2025-04-02 | Merck Sharp & Dohme Llc | Pharmaceutical composition containing an anti-nucleating agent |
| US20070259894A1 (en) | 2004-12-03 | 2007-11-08 | Kelem Kassahun | Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1 |
-
2005
- 2005-02-12 UA UAA200707372A patent/UA87884C2/uk unknown
- 2005-11-24 AR ARP050104911A patent/AR052034A1/es not_active Application Discontinuation
- 2005-11-25 TW TW094141625A patent/TWI344463B/zh not_active IP Right Cessation
- 2005-11-25 MY MYPI20055516A patent/MY144320A/en unknown
- 2005-12-01 PE PE2005001398A patent/PE20061148A1/es not_active Application Discontinuation
- 2005-12-02 CA CA2588398A patent/CA2588398C/en not_active Expired - Lifetime
- 2005-12-02 DK DK05852840.7T patent/DK1819700T3/da active
- 2005-12-02 RS RS20120021A patent/RS52197B/sr unknown
- 2005-12-02 WO PCT/US2005/043728 patent/WO2006060712A2/en not_active Ceased
- 2005-12-02 PT PT05852840T patent/PT1819700E/pt unknown
- 2005-12-02 ES ES05852866T patent/ES2370136T3/es not_active Expired - Lifetime
- 2005-12-02 MX MX2007006639A patent/MX2007006639A/es active IP Right Grant
- 2005-12-02 EP EP05852840A patent/EP1819700B1/de not_active Expired - Lifetime
- 2005-12-02 AT AT05852866T patent/ATE518844T1/de active
- 2005-12-02 PL PL05852840T patent/PL1819700T3/pl unknown
- 2005-12-02 KR KR1020137028450A patent/KR20130122031A/ko not_active Withdrawn
- 2005-12-02 JP JP2007544570A patent/JP4705956B2/ja not_active Expired - Lifetime
- 2005-12-02 CN CN2005800416393A patent/CN101068793B/zh not_active Expired - Lifetime
- 2005-12-02 WO PCT/US2005/043781 patent/WO2006060730A2/en not_active Ceased
- 2005-12-02 AT AT05852840T patent/ATE534645T1/de active
- 2005-12-02 GE GEAP200510157A patent/GEP20105086B/en unknown
- 2005-12-02 AU AU2005311671A patent/AU2005311671B8/en not_active Expired
- 2005-12-02 ME MEP-2012-21A patent/ME01985B/me unknown
- 2005-12-02 SI SI200531435T patent/SI1819700T1/sl unknown
- 2005-12-02 BR BRPI0518760A patent/BRPI0518760A8/pt not_active Application Discontinuation
- 2005-12-02 KR KR1020077015278A patent/KR101350420B1/ko not_active Expired - Lifetime
- 2005-12-02 US US11/293,678 patent/US7754731B2/en active Active
- 2005-12-02 EA EA200701204A patent/EA012418B1/ru not_active IP Right Cessation
- 2005-12-02 NZ NZ555376A patent/NZ555376A/en not_active IP Right Cessation
- 2005-12-02 ES ES05852840T patent/ES2375788T3/es not_active Expired - Lifetime
- 2005-12-02 HR HR20120066T patent/HRP20120066T1/hr unknown
- 2005-12-02 EP EP05852866A patent/EP1819683B1/de not_active Expired - Lifetime
-
2007
- 2007-05-22 ZA ZA200704130A patent/ZA200704130B/xx unknown
- 2007-05-23 CR CR9146A patent/CR9146A/es not_active Application Discontinuation
- 2007-05-28 NI NI200700138A patent/NI200700138A/es unknown
- 2007-05-31 IL IL183614A patent/IL183614A/en active IP Right Grant
- 2007-06-01 TN TNP2007000215A patent/TNSN07215A1/fr unknown
- 2007-06-29 MA MA30041A patent/MA29120B1/fr unknown
- 2007-07-02 NO NO20073404A patent/NO338784B1/no unknown
-
2010
- 2010-06-04 US US12/793,801 patent/US8357798B2/en not_active Expired - Lifetime
-
2012
- 2012-02-21 CY CY20121100173T patent/CY1112859T1/el unknown
-
2014
- 2014-04-24 AR ARP140101707A patent/AR101429A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE534645T1 (de) | Kaliumsalz eines hiv-integrasehemmers | |
| HUS2100022I1 (hu) | HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok | |
| ATE461202T1 (de) | Hiv-integrasehemmer | |
| CY2016028I1 (el) | S-τριαζολυλ αλφα-μερκαπτοακετανιλιδες ως αναστολεις της αντιστροφης μεταγραφασης του ηιv | |
| DK1749011T3 (da) | Bicykliske heterocykler som HIV-integrasehæmmere | |
| ATE405570T1 (de) | Hiv-integrase-inhibitoren: cyclische pyrimidinonverbindung | |
| EP1720856A4 (de) | Hiv-integrasehemmer | |
| MA28519B1 (fr) | Inhibiteurs de l'integrase du vih | |
| DK1962830T3 (da) | Azaindolhæmmere af aurorakinaser. | |
| DK1564210T5 (da) | 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer | |
| CY2014012I2 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
| EP1756069A4 (de) | Hiv-integrasehemmer | |
| DK1912949T3 (da) | Cyclohexylaminisoquinolon-derivater som inhibitorer af rho-kinase | |
| EP1788874A4 (de) | Salze von 5-azacytidin | |
| EP1725102A4 (de) | Hiv-integrasehemmer | |
| ATE459624T1 (de) | Inhibitoren der reversen transkriptase des hiv | |
| ITMI20041869A1 (it) | Nuovi inibitori delle istone deacetilasi | |
| EP1881825A4 (de) | Hiv-integrasehemmer | |
| EP1940406A4 (de) | Kaliumkanalinhibitoren | |
| DE602006006418D1 (de) | Hiv-protease-inhibitoren | |
| EP1993551A4 (de) | Kaliumkanalhemmer | |
| EP1981508A4 (de) | Kaliumkanalhemmer | |
| EP1910356A4 (de) | Hiv-integrasehemmer | |
| AP2008004400A0 (en) | Inhibitors of HIV integrase enzyme | |
| EP1909578A4 (de) | Hiv-integrasehemmer |